Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ: CLRB )

0.3126 -0.0003 (-0.10%)
Streaming Delayed Price Updated: 12:54 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectar Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
Via Benzinga
Earnings Preview For Cellectar Biosciences
Via Benzinga
Cellectar Biosciences to Present at the 37th Annual Roth Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
Via Benzinga
Exposures Fossil Fuels
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
Due to FDA communications, Cellectar Biosciences will explore options for development of its cancer drug. Focus on isotopes for solid tumors. 
Via Benzinga
Exposures Product Safety
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For November 18, 2024
Via Benzinga
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Cellectar Biosciences stock drops 19.2% following the release of CLOVER WaM study results. The pivotal study for iopofosine I 131 in relapsed/refractory Waldenstrom's macroglobulinemia showed an 80%... 
Via Benzinga
CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024
CLRB stock results show that Cellectar Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50%
Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains. 
Via InvestorPlace
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private. 
Via InvestorPlace
CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
CLRB stock results show that Cellectar Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
Via Benzinga
Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why
Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, achieving 64% complete remission and 73% overall response rate. Roth Capital... 
Via Benzinga
Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?
Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory... 
Via Benzinga
Wells Fargo Is Warming Up to Enphase Energy (ENPH) Stock
Enphase Energy stock is rising higher on Monday as investors react to a new upgrade and increased price target for ENPH from Wells Fargo. 
Via InvestorPlace
Why Is Spirit AeroSystems (SPR) Stock Down 14% Today?
Spirit AeroSystems stock is falling hard on Monday as investors in SPR react to one of the company's flights experiencing a mid-air blowout. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.